PharmaFocus Today – Page 90 – media

According to industry sources, AstraZeneca’s China structure will be adjusted

▍AstraZeneca’s China oncology business organizational structure is about to be adjusted According to multiple sources in the industry, the organizational structure of AstraZeneca’s China oncology business will be adjusted from January 1, 2025. The specific adjustments are as follows: First, the oncology business will establish four independent and collaborative business units/business units: lung cancer business unit, urogynecology and digestive oncology business unit, breast cancer business unit, and blood oncology business unit; Second, the marketing department and sales team At the same time as the structural adjustment, the executive team has also undergone certain changes—Zhang Lingyan: currently AstraZeneca China Vice President, Oncology Business Lung Cancer Business Unit and Gastrointestinal Oncology Business Head, will transfer and lead the Urogynecology and Gastrointestinal Oncology Business Unit, serve as AstraZeneca China Vice President, Oncology Business Urogynecology and Gastrointestinal Oncology Business Head; Breast Cancer Business Head: This position is recruited internally and externally, and is currently ...
- Source: drugdu
- 457
- December 31, 2024
Eli Lilly’s weight loss drug is officially on the market, and the price is higher than semaglutide

Novo Nordisk’s strongest rival for semaglutide is officially commercialized in China. On December 25, the reporter noticed that many e-commerce platforms have already provided diagnosis and treatment services for Eli Lilly’s glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist telpotide (trade name: Mufengda). Telpotide’s indications include diabetes and weight loss. Currently, the prices of various merchants on the platform are different, and the specific price is subject to the final selected store price. Eli Lilly’s telpotide can be purchased on multiple e-commerce platforms Taking a merchant in an Internet hospital as an example, the price of 0.5ml: 2.5mg*4 is 2,480 yuan. According to this calculation, the price of a single piece is 620 yuan. The merchant said that its drugs are authentic, quickly registered, and reserved. The reporter contacted the merchant’s customer service as a consumer, and the staff said that the drug can be used for weight loss and ...
- Source: drugdu
- 273
- December 31, 2024
African CDC Visits China National Biotech to Enhance Cooperation in Areas like Monkeypox

On December 17, a delegation from the Africa Centers for Disease Control and Prevention (Africa CDC), accompanied by Wang Lili, a deputy researcher at the Global Public Health Center of the Chinese Center for Disease Control and Prevention, and a group of 12 people, visited the Beijing Biological Products Institute of China National Biotech. Both parties expressed their commitment to further strengthen cooperation in the prevention and control of monkeypox and other infectious diseases, and to jointly promote the research, production, and application of vaccines, diagnostic reagents, and therapeutic drugs. Additionally, they will actively work towards achieving local production in Africa to improve the accessibility and affordability of vaccines and other medical products. https://finance.eastmoney.com/a/202412263279858541.html
- Source: drugdu
- 163
- December 30, 2024
Yingkerui’s “Class 1.1 New Drug for Autoimmune Chinese Medicine” has been approved for clinical trials

On December 24, according to the official website of CDE, Yingke Rui’s Class 1.1 new Chinese medicine “Shendai Rectal Suppository” obtained implicit approval for clinical trials. It is indicated for mild to moderate active ulcerative colitis with damp-heat and blood stasis syndrome. Inflammatory bowel disease (IBD) is a type of disease that causes inflammation of the digestive system, and the number of patients worldwide is on the rise. IBD mainly includes ulcerative colitis and Crohn’s disease, of which ulcerative colitis is common in patients aged 20 to 30 years old. Clinical manifestations include persistent or recurrent diarrhea, mucus, pus and blood in the stool accompanied by abdominal pain, and even skin lesions and mucosal lesions. At present, the cause of the disease has not been fully clarified. According to statistics, the global prevalence of ulcerative colitis in 2023 is about 5 million cases, and the incidence rate continues to show ...
- Source: drugdu
- 339
- December 30, 2024
Bristol-Myers Squibb “Big Purge”

On April 26, 2023, an unexpected announcement pushed Bristol-Myers Squibb into the spotlight. The announcement revealed the leadership transition of Bristol-Myers Squibb: its CEO Dr. Giovanni Caforio, after eight years in charge of the company, announced that he would step down and pass the leadership baton to Chief Commercialization Officer Chris Boerner. This marks the curtain call of Giovanni Caforio, and at the same time, it also brings unprecedented challenges to Chris Boerner. For Bristol-Myers Squibb, the severe test of the patent cliff is hanging over its head. In order to ensure a smooth transition, Caforio’s resignation is not effective immediately. After a carefully arranged transition period, Caforio will not officially hand over the baton until November 1, 2023, and a new chapter for Bristol-Myers Squibb will begin. This change of leadership is not only of great significance to Bristol-Myers Squibb itself, but also affects the fate of many biotechnology ...
- Source: drugdu
- 131
- December 30, 2024
The first new drug for chronic sinusitis with nasal polyps in China was approved

On December 23, Conoya announced that its independently developed Class 1 new drug Kangyueda® (Sepkibaimab Injection) was approved for marketing by the National Medical Products Administration for the treatment of chronic sinusitis with nasal polyps (CRSwNP). Previously, this indication was included in the priority review. The prevalence of chronic sinusitis in my country is 8%, of which about one-third are patients with chronic sinusitis with nasal polyps. The pathogenesis of chronic sinusitis with nasal polyps is complex, and the clinical symptoms such as nasal congestion, hyposmia and runny nose caused by it seriously affect the quality of life of patients. Clinically, the treatment of this disease faces difficulties such as refractory and recurrent, and innovative treatment methods are urgently needed. Kangyueda® (sipkizumab) is a highly effective, humanized monoclonal antibody targeting the interleukin-4 receptor α subunit (IL-4Rα). It is the first IL-4Rα antibody drug approved for marketing in China and the ...
- Source: drugdu
- 496
- December 30, 2024
Tirzepatide’s new indication is approved by the FDA, becoming the first drug to treat “snoring”

Today, Eli Lilly and Company announced that the U.S. FDA has approved its blockbuster therapy Zepbound (tirzepatide) to improve snoring in obese patients with moderate to severe obstructive sleep apnea (OSA). Zepbound can help these patients improve sleep disorders, but they need to be combined with a low-calorie diet and increased physical activity. Trial results show that after one year of Zepbound treatment, up to 50% of patients no longer have symptoms related to OSA. According to the press release, Zepbound is the first prescription drug approved for the treatment of obese patients with moderate to severe OSA. Frequent snoring may be a sign of OSA. This condition is caused by the complete or partial collapse of the patient’s upper airway during sleep, resulting in airway obstruction, which may cause apnea or weakened breathing, and may be accompanied by decreased blood oxygen saturation or waking up during sleep. OSA can ...
- Source: drugdu
- 348
- December 28, 2024
Another senior executive of Baiyunshan was taken away within half a year

On December 20, Baiyunshan (600332.SH) issued an announcement stating that it had received a written resignation report submitted by Huang Haiwen, the company’s deputy general manager, on the same day. “Due to personal reasons, Huang Haiwen resigned from the position of deputy general manager of the company and all positions in the company’s affiliated enterprises.” Baiyunshan said that after his resignation, Huang Haiwen no longer held all positions in the company and its affiliated enterprises. This is the third senior executive of Baiyunshan to announce his resignation from “all positions” this year, following the resignation of the company’s former chairman Li Chuyuan (later officially announced to be dismissed) in July this year and director Zhang Chunbo in August. Reporters confirmed from multiple independent information sources that Huang Haiwen has been taken away by relevant departments for investigation. It is worth noting that Huang Haiwen, 43 years old, has a resume ...
- Source: drugdu
- 141
- December 28, 2024
FDA approves first “off-the-shelf” mesenchymal cell therapy

The U.S. FDA recently announced that it has approved Ryoncil (remestemcel) developed by Mesoblast for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children aged 2 months and older. The FDA’s press release stated that this is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Ryoncil is a mesenchymal stromal cell produced by allogeneic bone marrow. It regulates T cell-mediated inflammatory responses by inhibiting T cell proliferation and downregulating the production of proinflammatory cytokines and interferons. The safety and efficacy of Ryoncil were verified in a multicenter, single-arm study in which 54 pediatric patients with SR-aGVHD after allo-HSCT participated. Study participants received intravenous infusions of Ryoncil twice a week for a total of four weeks. The main basis for efficacy is the remission rate and duration of remission 28 days after the start of treatment. Results showed that 16 participants (30%) achieved complete remission after 28 days of treatment ...
- Source: drugdu
- 271
- December 28, 2024
Longsha Capsules and Health Ingredients Expand Capsule Production Capacity in China and India

Longsha Capsules and Health Ingredients (CHI) has added new capsule production lines at its factories in Suzhou, China and Ravali, India, demonstrating its long-term strategic commitment to this business segment and the Asia Pacific region. This expansion aims to balance CHI’s global layout, meet regional demand, and promote technological upgrades. Basel, Switzerland, December 19, 2024- Lonza Group, as a manufacturing partner in the global pharmaceutical, biotechnology, and nutritional health markets, announced that its factories in Suzhou, China and Ravali, India will undergo capacity expansion. The expansion project includes the addition of a gelatin hollow capsule (HGC) production line to support the production of high-quality gelatin hard capsules. The types of capsules produced cover both conventional and customized capsules required by the pharmaceutical and nutritional health products industries. This capacity expansion marks another important progress in Longsha CHI’s hollow hard capsule strategy, aimed at enhancing long-term competitiveness and meeting high quality ...
- Source: drugdu
- 137
- December 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.